A detailed history of Pdt Partners, LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 52,474 shares of RARE stock, worth $2.16 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
52,474
Previous 47,501 10.47%
Holding current value
$2.16 Million
Previous $2.27 Million 7.88%
% of portfolio
0.24%
Previous 0.26%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$43.02 - $53.69 $213,938 - $267,000
4,973 Added 10.47%
52,474 $2.45 Million
Q4 2023

Feb 14, 2024

BUY
$31.73 - $49.19 $452,850 - $702,039
14,272 Added 42.95%
47,501 $2.27 Million
Q2 2023

Aug 14, 2023

BUY
$37.35 - $52.15 $1.24 Million - $1.73 Million
33,229 New
33,229 $1.53 Million
Q3 2021

Nov 15, 2021

SELL
$77.92 - $102.4 $945,091 - $1.24 Million
-12,129 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$92.19 - $115.71 $1.12 Million - $1.4 Million
12,129 New
12,129 $1.16 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $2.88B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.